Immunization of burn-patients with a Pseudomonas aeruginosa outer membrane protein vaccine elicits antibodies with protective efficacy.
The aim of this study was to determine whether the antibodies raised in burn patients by active immunization with a Pseudomonas aeruginosa OMPs vaccine have a protective efficacy against infection with P. aeruginosa. The binding patterns with P. aeruginosa OMPs of immunized burn patient sera were similar to the sera of immunized healthy humans as determined by immunoblot and immunoprecipitation analyses. The sera pooled from immunized burn patients after three immunizations showed a significantly higher opsonophagocytic-killing activity than the corresponding pre-immune sera, while the sera from unimmunized patients collected at the same day did not. Passive immunization of mice with post-immune sera of burn patients significantly enhanced the survival rate upon a lethal challenge with P. aeruginosa compared to the pre-immune sera, indicating the protective ability of the antibodies induced in burn patients by immunization. These results suggest that anti-P. aeruginosa OMPs antibodies elicited in burn patients by active immunization are protective against infection with P. aeruginosa, and provide a rational for further development of the vaccine for prevention against P. aeruginosa infection in burn patients.
Lee
N G
NG
R&D Center of Bioscience, Institute of Science and Technology, Cheiljedang Corp., Ichon, Kyonggi, South Korea.
Jung
S B
SB
Ahn
B Y
BY
Kim
Y H
YH
Kim
J J
JJ
Kim
D K
DK
Kim
I S
IS
Yoon
S M
SM
Nam
S W
SW
Kim
H S
HS
Park
W J
WJ
D000818:Animals; D000907:Antibodies, Bacterial / Q000096:biosynthesis* / Q000097:blood / Q000627:therapeutic use; D000937:Antigen-Antibody Reactions; D001425:Bacterial Outer Membrane Proteins / Q000276:immunology / Q000378:metabolism / Q000627:therapeutic use*; D001428:Bacterial Vaccines / Q000276:immunology / Q000627:therapeutic use*; D002056:Burns / Q000276:immunology* / Q000382:microbiology*; D006801:Humans; D007116:Immunization, Passive / Q000379:methods; D007074:Immunoglobulin G / Q000096:biosynthesis / Q000097:blood / Q000276:immunology; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D009895:Opsonin Proteins / Q000276:immunology; D010587:Phagocytosis / Q000276:immunology; D011552:Pseudomonas Infections / Q000517:prevention & control*; D011550:Pseudomonas aeruginosa / Q000276:immunology*; D011817:Rabbits; D015164:Vaccines, Inactivated / Q000276:immunology / Q000627:therapeutic use
D000907:Antibodies, Bacterial; D001425:Bacterial Outer Membrane Proteins; D001428:Bacterial Vaccines; D007074:Immunoglobulin G; D009895:Opsonin Proteins; D015164:Vaccines, Inactivated